MLTX
NASDAQMoonLake Immunotherapeutics
Price$21.21+4.52 (+27.11%)
2026-03-192026-06-23
News · 26 weeks45+200%
2025-12-282026-06-21
Mix2990d
- Insider13(45%)
- SEC Filings9(31%)
- Other5(17%)
- Offering2(7%)
Latest news
25 items- PRMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricing of an underwritten public offering of 9,000,000 Class A ordinary shares at a public offering price per share of $20.00 and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase up to 1,000,000 Class A ordinary shares at a public offering price per pre-funded warrant of $19.9999, which equals the public offering price per Class A ordinary share less the $0.0001 per share exercise price of each pre-funded wa
- INSIDERChief Financial Officer Bodenstedt Matthias sold $862,205 worth of Class A ordinary shares (39,120 units at $22.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,115,435 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- PRMoonLake Immunotherapeutics Announces Proposed Public OfferingZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced a proposed public offering of $150 million of its Class A ordinary shares and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase Class A ordinary shares. In addition, MoonLake is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $22.5 million of its Class A ordinary shares offered in the proposed offering at the public offering price, less the under
- SECSEC Form 424B5 filed by MoonLake Immunotherapeutics424B5 - MoonLake Immunotherapeutics (0001821586) (Filer)
- INSIDERSEC Form 4 filed by Director Bvf Partners L P/Il4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SECMoonLake Immunotherapeutics filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- PRMoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than those observed in trials of competing agents at the end of their respective parental trialsNamely, ~67% of patients treated with SLK achieved HiSCR75 at the one-year mark, with more than one quarter of patients achieving inflammatory remission (IHS4-100), and around one third reaching HiSCR100Patients treated with SLK likewise showed substantial improvement in HiSQOL at Week 52, with a mean score difference between end of trial and baseline of
- INSIDERSEC Form 4 filed by Director Phillips Andrew John4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERChief Financial Officer Bodenstedt Matthias sold $351,576 worth of Class A ordinary shares (17,876 units at $19.67) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,154,555 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Director Loy Spike4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Director Xavier Ramnik4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Director Moukheibir Catherine4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERChief Scientific Officer Reich Kristian sold $2,851,000 worth of Class A ordinary shares (150,000 units at $19.01) as part of a pre-agreed trading plan (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SECMoonLake Immunotherapeutics filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECMoonLake Immunotherapeutics filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MoonLake ImmunotherapeuticsSCHEDULE 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
- INSIDERChief Financial Officer Bodenstedt Matthias sold $273,333 worth of Class A ordinary shares (13,653 units at $20.02) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,172,431 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SECSEC Form 10-Q filed by MoonLake Immunotherapeutics10-Q - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECMoonLake Immunotherapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- PRMoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial ResultsMoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where MoonLake and the FDA aligned on submission plans and the label strategy for sonelokimab (SLK) in hidradenitis suppurativa (HS)This included the acceptability of MIRA trial data to establish substantial evidence of effectiveness (SEE), full inclusion of the VELA-TEEN trial data for a label including patients aged 12 years and above, and the strategy for inclusion of safety data across the MIRA and VELA trials – this aligns with the scenario presented at the Investor Day on February 23, 2026The proposed label in HS is therefore expected to include the MIRA
- SECSEC Form DEFA14A filed by MoonLake ImmunotherapeuticsDEFA14A - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECSEC Form DEF 14A filed by MoonLake ImmunotherapeuticsDEF 14A - MoonLake Immunotherapeutics (0001821586) (Filer)
- INSIDERSEC Form 4 filed by Bodenstedt Matthias4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Santos Da Silva Jorge4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Bodenstedt Matthias4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
MLTX FAQ
7 questionsWhat does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.Where does MLTX stock trade?
MoonLake Immunotherapeutics (MLTX) is listed on NASDAQ.What sector and industry is MLTX in?
MoonLake Immunotherapeutics operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MoonLake Immunotherapeutics go public?
MoonLake Immunotherapeutics (MLTX) completed its IPO in 2020.What are analysts saying about MLTX?
MoonLake Immunotherapeutics has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $2400.00 price target on 2026-03-23.What companies are similar to MLTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MLTX side-by-side with any of them on Quantisnow.How can I track MLTX on Quantisnow?
Quantisnow aggregates MoonLake Immunotherapeutics's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MLTX to receive live email and push alerts on every new disclosure.